PitchSend

Nuvectis Pharma Investor Presentation Deck

Substantial Antitumor Activity in Cholangiocarcinoma Additional potential development opportunities ◆ Cholangiocarcinoma (CCA) is a lethal malignancy with poor prognosis arising from the biliary tree Approx. 10,000 new cases/year in the US a a. The cholangiocarcinoma foundation, cholangiocarcinoma.org/key-statistics NuvectisPharma, Inc. Delta in Tumor Volume (mm³) Patient Resection and PDX Implantation 1000- 500- Vehicle NPX800 CCA Tumor 12 Treatment days 15 18 27 NXP800 Treatment Initiation Day 0 Treatment 5 days on, 2 days off Vehicle NXP800 D Carlson, 2023 American Association for Cancer Research PDX Euthanasia Day 22-30 | 10

View entire presentation